Clinical Trial Update: CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CPG10101 in combination therapy for chronic hepatitis C genotype 1 in non-responders, with the study status reported as complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• CPG10101

Snippet

Sponsor: Pfizer | Conditions: Hepatitis, Chronic Active | Phase 2 | Status: COMPLETED